JP2003522200A5 - - Google Patents

Download PDF

Info

Publication number
JP2003522200A5
JP2003522200A5 JP2001558103A JP2001558103A JP2003522200A5 JP 2003522200 A5 JP2003522200 A5 JP 2003522200A5 JP 2001558103 A JP2001558103 A JP 2001558103A JP 2001558103 A JP2001558103 A JP 2001558103A JP 2003522200 A5 JP2003522200 A5 JP 2003522200A5
Authority
JP
Japan
Prior art keywords
amino acid
heavy chain
change
preferred
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001558103A
Other languages
English (en)
Japanese (ja)
Other versions
JP5179689B2 (ja
JP2003522200A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/004455 external-priority patent/WO2001058957A2/en
Publication of JP2003522200A publication Critical patent/JP2003522200A/ja
Publication of JP2003522200A5 publication Critical patent/JP2003522200A5/ja
Application granted granted Critical
Publication of JP5179689B2 publication Critical patent/JP5179689B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

JP2001558103A 2000-02-11 2001-02-09 抗体ベース融合タンパク質の循環系内半減期の増強 Expired - Fee Related JP5179689B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18176800P 2000-02-11 2000-02-11
US60/181,768 2000-02-11
PCT/US2001/004455 WO2001058957A2 (en) 2000-02-11 2001-02-09 Enhancing the circulating half-life of antibody-based fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012108394A Division JP5572665B2 (ja) 2000-02-11 2012-05-10 抗体ベース融合タンパク質の循環系内半減期の増強

Publications (3)

Publication Number Publication Date
JP2003522200A JP2003522200A (ja) 2003-07-22
JP2003522200A5 true JP2003522200A5 (enExample) 2012-07-05
JP5179689B2 JP5179689B2 (ja) 2013-04-10

Family

ID=22665708

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001558103A Expired - Fee Related JP5179689B2 (ja) 2000-02-11 2001-02-09 抗体ベース融合タンパク質の循環系内半減期の増強
JP2012108394A Expired - Lifetime JP5572665B2 (ja) 2000-02-11 2012-05-10 抗体ベース融合タンパク質の循環系内半減期の増強

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012108394A Expired - Lifetime JP5572665B2 (ja) 2000-02-11 2012-05-10 抗体ベース融合タンパク質の循環系内半減期の増強

Country Status (16)

Country Link
US (3) US7091321B2 (enExample)
EP (1) EP1252192B1 (enExample)
JP (2) JP5179689B2 (enExample)
CN (1) CN1406249B (enExample)
AT (1) ATE336514T1 (enExample)
AU (1) AU4314801A (enExample)
CA (1) CA2399832C (enExample)
CY (1) CY1105725T1 (enExample)
DE (1) DE60122286T2 (enExample)
DK (1) DK1252192T3 (enExample)
ES (1) ES2269366T3 (enExample)
HU (1) HUP0204475A2 (enExample)
MX (1) MXPA02007733A (enExample)
NO (1) NO20023774D0 (enExample)
PT (1) PT1252192E (enExample)
WO (1) WO2001058957A2 (enExample)

Families Citing this family (308)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US7387772B1 (en) * 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR20020018197A (ko) * 1999-05-19 2002-03-07 추후보정 Ｆｃ 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
CZ2003214A3 (cs) * 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
BR0209177A (pt) 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
SI1471974T1 (sl) * 2002-02-06 2007-12-31 Ares Trading Sa Tumorje nekrotizirajoäśi faktor, kombiniran z interferonom, pri demielinizirajoäśih boleznih
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
WO2004021861A2 (en) * 2002-09-03 2004-03-18 Vit Lauermann Targeted release
US20060020396A1 (en) * 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
SI1624891T2 (sl) 2003-05-06 2013-09-30 Biogen Idec Hemophilia Inc. Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
KR101163424B1 (ko) 2003-12-30 2012-07-13 메르크 파텐트 게엠베하 Ｉｌ－７ 융합 단백질
EP1699821B1 (en) * 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
CA2552590A1 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
CA2553883C (en) * 2004-01-22 2013-04-02 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
AU2005277641A1 (en) * 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
CN101072793B (zh) * 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
CN100429233C (zh) * 2005-02-03 2008-10-29 上海长海医院 一种重组融合蛋白及其制备方法及用途
PT1853718E (pt) 2005-02-15 2015-11-12 Univ Duke Anticorpos anti-cd19 e usos em oncologia
US20060263357A1 (en) 2005-05-05 2006-11-23 Tedder Thomas F Anti-CD19 antibody therapy for autoimmune disease
CA2606102C (en) * 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
WO2007005612A2 (en) 2005-07-01 2007-01-11 Medimmune, Inc. An integrated approach for generating multidomain protein therapeutics
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
AU2006304387A1 (en) 2005-10-14 2007-04-26 Medimmune, Llc Cell display of antibody libraries
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP2500360B1 (en) * 2005-10-31 2015-08-05 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
SI1966238T1 (sl) * 2005-12-30 2012-08-31 Merck Patent Gmbh Variante interlevkina-12P40 z izboljšano stabilnostjo
JP2009525986A (ja) * 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2650306A1 (en) 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US7932055B2 (en) 2006-06-22 2011-04-26 Novo Nordisk A/S Soluble heterodimeric CD94/NKG2 receptors fusion proteins
DE602006016765D1 (de) 2006-06-30 2010-10-21 Conaris Res Inst Ag Verbesserte sgp 130Fc Dimere
JP2009542592A (ja) * 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
TW200817438A (en) * 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
AR062709A1 (es) * 2006-09-08 2008-11-26 Genentech Inc Antagonistas del gen wnt y su uso en el diagnostico y tratamiento de trastornos mediados por el wnt
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
BRPI0811466A2 (pt) 2007-05-07 2014-10-14 Medimmune Llc Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
CN105175553B (zh) * 2007-05-30 2019-11-22 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
CN101687933B (zh) * 2007-05-30 2015-11-25 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US20110077383A1 (en) * 2007-07-03 2011-03-31 Medimmune, Llc Hinge domain engineering
AR067537A1 (es) * 2007-07-17 2009-10-14 Hoffmann La Roche Purificacion de polipeptidos pegilados
CL2008002054A1 (es) * 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
AR067584A1 (es) * 2007-07-20 2009-10-14 Hoffmann La Roche Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
MX2010006735A (es) 2007-12-21 2010-09-30 Medimmune Ltd Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
KR20100107501A (ko) 2008-01-18 2010-10-05 메디뮨 엘엘씨 부위 특이적 접합을 위한 시스테인 조작 항체
CA2715043C (en) * 2008-02-05 2021-02-16 Zymeworks Inc. Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
CN102066575A (zh) * 2008-04-18 2011-05-18 雅培制药有限公司 结合蛋白体内半衰期的体外估测
EP2331136B1 (en) 2008-09-26 2018-01-10 OncoMed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
WO2010056804A1 (en) 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
US8775090B2 (en) 2008-12-12 2014-07-08 Medimmune, Llc Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
WO2010085495A1 (en) 2009-01-21 2010-07-29 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
AU2010238858A1 (en) 2009-04-22 2011-12-08 Merck Patent Gmbh Antibody fusion proteins with modified FcRn binding sites
BRPI1015234A2 (en) 2009-06-22 2018-02-20 Medimmune Llc fc regions designed for site specific conjugation.
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
EP2722055A1 (en) 2009-08-17 2014-04-23 Tracon Pharmaceuticals, Inc. Combination therapy with antibodies and anti-VEGF agents for the treatment of cancer
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
MX2012004029A (es) 2009-10-07 2012-05-08 Macrogenics Inc Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
EP2507267B1 (en) * 2009-12-02 2016-09-14 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life of fc fusion proteins
EP4382170A3 (en) 2009-12-06 2024-09-04 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
SG10201503351RA (en) * 2010-01-19 2015-06-29 Harvard College Engineered Opsonin for Pathogen Detection and Treatment
AR080154A1 (es) 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos cd20 y su utilizacion
CN102971337B (zh) 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
MX375112B (es) 2010-07-09 2025-03-06 Biogen Hemophilia Inc Polipéptidos de factor ix y métodos para usarlos.
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
ES2500048T3 (es) 2010-09-14 2014-09-29 F. Hoffmann-La Roche Ag Procedimiento para purificar eritropoyetina pegilada
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
EP3415528B1 (en) 2011-04-13 2021-05-26 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
AU2012280474A1 (en) 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
AU2012283235A1 (en) 2011-07-08 2014-01-09 Bayer Intellectual Property Gmbh Fusion proteins releasing Relaxin and uses thereof
EP4169525A1 (en) 2011-07-08 2023-04-26 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
EA028914B1 (ru) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
DK2760471T3 (en) 2011-09-30 2017-05-08 Dana Farber Cancer Inst Inc THERAPEUTIC PEPTIDES
CN104203982B (zh) 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
CN103906533A (zh) 2011-11-07 2014-07-02 米迪缪尼有限公司 多特异性和多价结合蛋白及其用途
EP3539982B1 (en) 2011-12-23 2025-02-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EA038705B1 (ru) 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
PL2822575T3 (pl) * 2012-03-03 2020-08-10 Immungene, Inc. Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu
PL3489254T3 (pl) 2012-04-30 2023-01-30 Biocon Limited Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
SI3495387T1 (sl) 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
EP4063391A1 (en) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
SG11201408530YA (en) * 2012-08-02 2015-03-30 Hoffmann La Roche Method for producing monomeric and multimeric molecules and uses thereof
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
WO2014052490A1 (en) 2012-09-25 2014-04-03 Biogen Idec Ma Inc. Methods of using fix polypeptides
AU2013331000B2 (en) 2012-10-18 2018-04-19 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
JP2015536933A (ja) 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路結合剤を用いて神経内分泌腫瘍を処置する方法
WO2014070953A1 (en) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
EP2956468B1 (en) 2013-02-12 2020-06-10 Bristol-Myers Squibb Company Tangential flow filtration based protein refolding methods
US10065987B2 (en) 2013-02-12 2018-09-04 Bristol-Myers Squibb Company High pH protein refolding methods
MY186864A (en) 2013-03-12 2021-08-26 Biocon Ltd Fusion immunomodulatory proteins and methods for making same
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
WO2014144791A2 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
CA2904357C (en) 2013-03-15 2020-09-22 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
ES2926798T3 (es) 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII
JP2016518361A (ja) 2013-04-19 2016-06-23 シーチューヌ ファルマＣｙｔｕｎｅ Ｐｈａｒｍａ 血管漏出症候群の発生を抑制するサイトカイン治療
US9963515B2 (en) 2013-04-29 2018-05-08 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
EP3848045A1 (en) 2013-05-21 2021-07-14 President and Fellows of Harvard College Engineered heme-binding compositions and uses thereof
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
SG11201602522VA (en) 2013-10-02 2016-04-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
MX371187B (es) 2013-12-06 2020-01-22 Dana Farber Cancer Inst Inc Péptidos terapéuticos.
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US10513546B2 (en) 2013-12-18 2019-12-24 President And Fellows Of Harvard College CRP capture/detection of gram positive bacteria
CN106103476B (zh) 2013-12-24 2020-11-27 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
HRP20210977T1 (hr) 2014-02-10 2021-09-17 Merck Patent Gmbh Ciljano inhibiranje tgf beta
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3116903A2 (en) 2014-03-14 2017-01-18 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
EA202092926A3 (ru) 2014-03-24 2021-10-29 Биовератив Терапьютикс Инк. Лиофилизированные составы, содержащие фактор ix
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
WO2016011035A2 (en) 2014-07-15 2016-01-21 Medlmmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
WO2016023916A1 (en) 2014-08-12 2016-02-18 Kymab Limited Treatment of disease using ligand binding to targets of interest
CA2961917A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
PE20170908A1 (es) 2014-10-29 2017-07-12 Teva Pharmaceuticals Australia Pty Ltd VARIANTES DE INTERFERON a2b
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
WO2016071701A1 (en) 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
ES2826566T3 (es) 2014-11-21 2021-05-18 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
KR20240131465A (ko) 2014-12-01 2024-08-30 훼링 비.브이. 선택적 il-6-트랜스-신호전달 억제제 조성물
EP3226888B1 (en) 2014-12-01 2021-04-21 Ferring B.V. Administration of a selective il-6-trans-signalling inhibitor
AR103268A1 (es) 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
MX386491B (es) 2015-03-09 2025-03-18 argenx BV Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn.
IL304950A (en) 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
AU2016271111B2 (en) 2015-05-29 2022-04-28 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
US10435457B2 (en) 2015-08-06 2019-10-08 President And Fellows Of Harvard College Microbe-binding molecules and uses thereof
UA128469C2 (uk) 2015-10-08 2024-07-24 Макродженікс, Інк. Спосіб лікування в7-н3-експресуючого раку
MX2018006072A (es) 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
AR108034A1 (es) 2016-02-17 2018-07-11 Macrogenics Inc Moléculas de unión a ror1, y métodos de uso de las mismas
AU2017228470A1 (en) 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
AU2017234679A1 (en) 2016-03-16 2018-08-30 Merrimack Pharmaceuticals, Inc. Engineered trail for cancer therapy
CN109069633A (zh) 2016-04-15 2018-12-21 宏观基因有限公司 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
US10968279B2 (en) 2016-05-09 2021-04-06 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US20190248893A1 (en) 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2018011381A1 (en) 2016-07-15 2018-01-18 F. Hoffmann-La Roche Ag Method for purifying pegylated erythropoietin
JP7573365B2 (ja) 2016-08-12 2024-10-25 メルク パテント ゲーエムベーハー 癌の併用療法
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
AU2017363309A1 (en) 2016-11-23 2019-07-11 Bioverativ Therapeutics Inc. Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
CA3044838A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MD3558391T2 (ro) 2016-12-23 2022-05-31 Immunogen Inc Imunoconjugate care țintesc ADAM9 și procedee de utilizare a acestora
BR112019012950A2 (pt) 2016-12-23 2019-11-26 Macrogenics, Inc. molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
EP3600429B1 (en) * 2017-03-20 2023-10-25 Bio-Techne Corporation Il-37 fusion protein and methods of making and using same
WO2018213097A1 (en) 2017-05-15 2018-11-22 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
MX2019013132A (es) 2017-05-25 2020-01-27 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas.
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
CN111247171A (zh) 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
MA51032A (fr) 2017-12-08 2021-03-17 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
US11795226B2 (en) 2017-12-12 2023-10-24 Macrogenics, Inc. Bispecific CD16-binding molecules and their use in the treatment of disease
JP7765181B2 (ja) 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたｉｌ－２ ｆｃ融合タンパク質
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
US12139533B2 (en) 2017-12-20 2024-11-12 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-CD200 antibodies
JP7358361B2 (ja) 2018-01-12 2023-10-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
CN111699004A (zh) 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
CN111787949A (zh) 2018-02-15 2020-10-16 宏观基因有限公司 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
SG11202008593PA (en) 2018-03-21 2020-10-29 Five Prime Therapeutics Inc ANTIBODIES BINDING TO VISTA AT ACIDIC pH
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
CR20250022A (es) 2018-04-02 2025-02-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450)
CA3096703A1 (en) 2018-05-03 2019-11-07 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
JP7486437B2 (ja) 2018-06-08 2024-05-17 アルジェニクス ビーブイ 免疫性血小板減少症を治療する組成物及び方法
MX2020013466A (es) 2018-06-26 2021-04-19 Immunogen Inc Inmunoconjugados dirigidos a adam9 y métodos para usarlos.
MY201995A (en) 2018-07-09 2024-03-28 Five Prime Therapeutics Inc Antibodies binding to ilt4
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
AU2019301120A1 (en) 2018-07-11 2021-02-25 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
KR102884523B1 (ko) 2018-10-03 2025-11-10 젠코어 인코포레이티드 IL-12 이종이량체 Fc-융합 단백질
EP3863722A2 (en) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap antibody variants and uses thereof
TWI897855B (zh) 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
CN119033684A (zh) 2018-10-29 2024-11-29 豪夫迈·罗氏有限公司 抗体制剂
CA3117429A1 (en) 2018-11-01 2020-05-07 Merck Patent Gmbh Anti-tim-3 antibodies
AU2019372436A1 (en) 2018-11-01 2021-05-20 Merck Patent Gmbh Methods of administering anti-TIM-3 antibodies
JP2022513653A (ja) 2018-11-28 2022-02-09 ブリストル－マイヤーズ スクイブ カンパニー 修飾された重鎖定常領域を含む抗体
US12428484B2 (en) 2018-12-06 2025-09-30 Alexion Pharmaceuticals, Inc. Anti-ALK2 antibodies and uses thereof
US20220056135A1 (en) 2018-12-21 2022-02-24 Ose Immunotherapeutics Bifunctional anti-pd-1/sirpa molecule
CN113573782B (zh) 2018-12-21 2025-12-16 Ose免疫疗法公司 针对人pd-1的双功能分子
AU2019406452B2 (en) 2018-12-21 2021-09-16 Ose Immunotherapeutics Humanized anti-human-PD-1 antibody
WO2020127377A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
CN118894938A (zh) 2019-01-22 2024-11-05 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
CN113811549A (zh) 2019-02-21 2021-12-17 Xencor股份有限公司 非靶向和靶向性il-10 fc融合蛋白
GB2589049C (en) 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
EP3969119A1 (en) 2019-05-17 2022-03-23 Xencor, Inc. Il-7-fc-fusi0n proteins
BR112021024632A2 (pt) 2019-06-07 2022-01-18 Argenx Bvba Formulações farmacêuticas de inibidores de fcrn adequados para administração subcutânea
WO2021011678A1 (en) 2019-07-15 2021-01-21 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
EP3999541A1 (en) 2019-07-15 2022-05-25 Bristol-Myers Squibb Company Antibodies against human trem-1 and uses thereof
CN114555634B (zh) 2019-08-13 2025-01-10 美国安进公司 用于扩增调节性t细胞的白介素-2突变蛋白
CA3149719A1 (en) 2019-09-19 2021-03-25 Bristol-Myers Squibb Company Antibodies binding to vista at acidic ph
EP4037700A2 (en) 2019-10-03 2022-08-10 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ｏｓｅ免疫治療公司 包含il-7變體之雙官能分子
ES2992247T3 (es) 2020-01-08 2024-12-11 argenx BV Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
JP7745556B2 (ja) 2020-02-21 2025-09-29 マクロジェニクス，インコーポレーテッド Ｃｄ１３７結合分子及びその使用
WO2021202235A1 (en) 2020-04-01 2021-10-07 University Of Rochester Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
EP4132971A1 (en) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinity matured anti-lap antibodies and uses thereof
US11634477B2 (en) 2020-04-28 2023-04-25 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
US20240279353A1 (en) 2020-07-06 2024-08-22 Kiromic BioPharma, Inc. Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US11919945B2 (en) 2020-11-04 2024-03-05 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies
CA3202233A1 (en) 2020-11-18 2022-05-27 Kiromic BioPharma, Inc. Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
AU2021402065A1 (en) 2020-12-17 2023-06-29 Boehringer Ingelheim International Gmbh Bifunctional anti-pd1/il-7 molecules
WO2022127793A1 (zh) 2020-12-18 2022-06-23 珠海泰诺麦博生物技术有限公司 呼吸道合胞病毒特异性结合分子
EP4277926A1 (en) 2021-01-15 2023-11-22 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
MX2023011964A (es) 2021-04-09 2024-01-08 Ose Immunotherapeutics Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
AU2022307460A1 (en) * 2021-07-09 2024-01-04 Bright Peak Therapeutics Ag Checkpoint inhibitors conjugated to il-2, and uses thereof
KR20240034221A (ko) 2021-07-09 2024-03-13 브라이트 피크 테라퓨틱스 아게 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드
US20230201364A1 (en) * 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Antibody conjugates and manufacture thereof
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
CN118541392A (zh) 2021-09-28 2024-08-23 准星生物医药有限公司 多种形式的分子复合物
EP4469159A1 (en) 2022-01-27 2024-12-04 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
KR20250037789A (ko) 2022-06-15 2025-03-18 아르젠엑스 비브이 Fcrn/항원-결합 분자 및 사용 방법
CN119630428A (zh) 2022-07-12 2025-03-14 西托姆克斯治疗公司 Epcam免疫缀合物及其用途
EP4558529A1 (en) 2022-07-22 2025-05-28 Bristol-Myers Squibb Company Antibodies binding to human pad4 and uses thereof
EP4565610A1 (en) 2022-08-02 2025-06-11 Ose Immunotherapeutics Multifunctional molecule directed against cd28
KR20250167153A (ko) 2023-03-03 2025-11-28 셀덱스 쎄라퓨틱스, 인크. 항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물
EP4688851A1 (en) 2023-03-27 2026-02-11 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use
WO2025012118A2 (en) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
US20250109187A1 (en) 2023-09-28 2025-04-03 Novavax, Inc. ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19
CN122422333A (zh) 2023-10-17 2026-07-17 百时美施贵宝公司 Gspt1降解化合物、抗cd33抗体和抗体-药物缀合物及其用途
WO2025094146A1 (en) 2023-11-02 2025-05-08 Immunogen Switzerland Gmbh Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates
WO2025133694A1 (en) 2023-12-20 2025-06-26 argenx BV Fcrn/hsa-binding molecules and methods of use
GB202319605D0 (en) 2023-12-20 2024-01-31 argenx BV Monovalent binding molecules and methods of use
WO2025155877A2 (en) 2024-01-18 2025-07-24 The Regents Of The University Of California Antibodies binding to pad4 and uses thereof
WO2025174974A1 (en) 2024-02-14 2025-08-21 Bristol-Myers Squibb Company Anti-cd33 antibodies and uses thereof
US12521446B2 (en) 2024-02-27 2026-01-13 Bristol-Myers Squibb Company Anti-CEACAM5 antibody drug conjugates
US20250361320A1 (en) 2024-02-27 2025-11-27 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
US20260092096A1 (en) 2024-05-14 2026-04-02 35Pharma Inc. Activin receptor type iib variants and uses thereof
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2025245176A1 (en) 2024-05-22 2025-11-27 Bristol-Myers Squibb Company Multispecific antibody constructs
WO2025242836A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
US20250376536A1 (en) 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Multispecific anti-cd40 / anti-fap antibodies and uses thereof
TW202607016A (zh) 2024-06-06 2026-02-16 美商必治妥美雅史谷比公司 抗fap抗體及其用途
WO2026068705A1 (en) 2024-09-26 2026-04-02 Ose Immunotherapeutics Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof
WO2026068750A1 (en) 2024-09-27 2026-04-02 Biomunex Pharmaceuticals Antibodies that specifically bind mucosal associated invariant t (mait) cells
WO2026096695A1 (en) 2024-10-31 2026-05-07 Bristol-Myers Squibb Company Anti-fucosyl-gm1 antibody drug conjugates
US20260144884A1 (en) 2024-11-22 2026-05-28 Bristol-Myers Squibb Company Anti-lrrc15 antibody drug conjugates
US20260144885A1 (en) 2024-11-22 2026-05-28 Bristol-Myers Squibb Company Anti-lrrc15 antibodies and uses thereof
WO2026128221A1 (en) 2024-12-12 2026-06-18 University Of Rochester Antt-tgfbp3 antibodies to treat cancer and sarcopenia
WO2026143022A1 (en) 2024-12-23 2026-07-02 Point Loma Nazarene University Antibody directed enzyme pro-drug therapy (adept) for cancer treatment using an antibody or fragment that binds to a cd206 receptor and 3-cyclopentyl-alpha-phenylalanine-methotrexate
WO2026150085A1 (en) 2025-01-10 2026-07-16 argenx BV Igg-binding molecules and methods of use thereof
WO2026161794A1 (en) 2025-01-27 2026-07-30 Cytomx Therapeutics, Inc. Epcam immunoconjugates and therapeutic uses thereof

Family Cites Families (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4469797A (en) 1982-09-23 1984-09-04 Miles Laboratories, Inc. Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US5082658A (en) 1984-01-16 1992-01-21 Genentech, Inc. Gamma interferon-interleukin-2 synergism
EP0158198A1 (en) 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA and use thereof
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4667016A (en) 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5679543A (en) 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US5643565A (en) 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
DE3712985A1 (de) 1987-04-16 1988-11-03 Hoechst Ag Bifunktionelle proteine
US5359035A (en) 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
JPS63267278A (ja) 1986-03-14 1988-11-04 Toray Ind Inc インタ−フエロン結合体を暗号化する塩基配列
EP0237019A3 (en) 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DK173067B1 (da) * 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4894227A (en) 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5508031A (en) 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
US4732683A (en) 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
ATE122238T1 (de) 1987-06-10 1995-05-15 Dana Farber Cancer Inst Inc Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen.
US5064646A (en) 1988-08-02 1991-11-12 The University Of Maryland Novel infectious bursal disease virus
PH26813A (en) 1987-09-02 1992-11-05 Ciba Geigy Ag Conjugates of cytokines with immunoglobulins
CA1338518C (en) 1987-09-23 1996-08-13 Joyce M. Zarling Antibody heteroconjugates for the killing of hiv-infected cells
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
AU2635088A (en) 1987-12-04 1989-06-08 Du Pont Merck Pharmaceutical Company, The Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
CA1341588C (en) 1988-01-26 2009-01-06 Michel Revel Human ifn-beta2/i1-6, its purification and use
US5120525A (en) 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
DE3812605A1 (de) 1988-04-15 1990-06-07 Leskovar Peter Dipl Ing Dr Hab Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
IT1217724B (it) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
IE62463B1 (en) 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
IL91933A (en) 1988-10-11 1994-12-29 Univ Southern California Vasoactive immunoconjugates useful for increasing the vascular permeability or the blood supply to neoplastic or otherwise diseased tissues
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5242824A (en) 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US6750329B1 (en) 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
DE69019609T2 (de) 1989-07-07 1995-11-30 Takeda Chemical Industries Ltd Proteine und deren Herstellung.
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
DE69034022T2 (de) 1989-09-20 2003-07-10 Abbott Laboratories, Abbott Park Verfahren zur Herstellung von Fusionsproteinen
AU646822B2 (en) 1989-10-13 1994-03-10 Kirin-Amgen Inc. Erythropoietin isoforms
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
DK0433827T3 (da) 1989-12-22 1998-09-28 Hoffmann La Roche Cytotoksisk lumfocytmodningsfaktor
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
EP0517754A1 (en) 1990-03-02 1992-12-16 Repligen Corporation Antibody constructs with enhanced binding affinity
DE69127749T2 (de) 1990-03-20 1998-04-16 The Trustees Of Columbia University In The City Of New York, New York, N.Y. Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US7253264B1 (en) * 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
EP0541716A1 (en) 1990-07-27 1993-05-19 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
WO1992008801A1 (en) 1990-11-09 1992-05-29 Abbott Laboratories Bridging antibody fusion constructs
DK0561907T3 (da) 1990-12-05 1999-05-31 Novo Nordisk As Proteiner med ændrede epitoper og fremgangsmåder til fremstilling deraf
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
GB9105245D0 (en) 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
US6072039A (en) 1991-04-19 2000-06-06 Rohm And Haas Company Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
WO1993003157A1 (en) 1991-07-29 1993-02-18 Dana Farber Cancer Institute Plasmids for the rapid preparation of modified proteins
AU666866B2 (en) 1991-08-30 1996-02-29 Fred Hutchinson Cancer Research Center Hybrid cytokines
US20020037558A1 (en) 1991-10-23 2002-03-28 Kin-Ming Lo E.coli produced immunoglobulin constructs
US5376367A (en) 1991-11-22 1994-12-27 Immunex Corporation Fusion proteins comprising MGF and IL-3
US6627615B1 (en) 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
PT633929E (pt) 1992-04-01 2004-07-30 Merix Bioscience Inc Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios
AU687733B2 (en) 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
ATE311895T1 (de) 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
EP0671926B1 (en) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
DE4228839A1 (de) * 1992-08-29 1994-03-03 Behringwerke Ag Verfahren zum Nachweis und zur Bestimmung von Mediatoren
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
EP1757695A3 (en) 1992-11-05 2008-02-27 Sloan Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5738849A (en) 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5543297A (en) 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
KR960701988A (ko) 1993-04-20 1996-03-28 윌리엄 에스. 로빈슨 세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents)
WO1994024160A2 (en) 1993-04-21 1994-10-27 Brigham And Women's Hospital Erythropoietin muteins with enhanced activity
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
WO1994025609A1 (en) 1993-04-28 1994-11-10 Hybritech Incorporated Method for creating optimized regulatory regions affecting protein expression and protein trafficking
KR960701650A (ko) 1993-04-29 1996-03-28 찰스 엠. 브룩 에리트로포이에틴 유사체 조성물 및 방법(Eythropoietin analog compositions and methods)
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
CA2125763C (en) 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
GB9316989D0 (en) 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
DE69521789T2 (de) 1994-02-01 2002-04-25 The United States Of Amerika Represented By The Secretary, Department Of Health And Human Fusionierte proteine die antikörper-teile und nicht-antikörper-teile enthalten
WO1995028427A1 (en) 1994-04-15 1995-10-26 Imclone Systems Incorporated Chimeric interleukin-3/mutein interleukin-6 lymphokine
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
CN1636594B (zh) 1994-04-26 2012-08-29 儿童医学中心公司 血管生成抑制素和用于抑制血管生成的方法
DK0759944T3 (da) 1994-05-13 2001-11-26 Biovation Ltd Forbedringer af og relateret til peptidfremføring
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
CZ25697A3 (en) 1994-07-29 1997-09-17 Smithkline Beecham Plc Novel compounds
US5888773A (en) 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
PT706799E (pt) 1994-09-16 2002-05-31 Merck Patent Gmbh Imunoconjugados ii
CA2205572A1 (en) * 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5691309A (en) 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
EP0815224B1 (en) 1995-03-10 2004-07-21 Genentech, Inc. Receptor activation by gas6
US5719266A (en) 1995-03-17 1998-02-17 Eli Lilly And Company Anti-obesity proteins
AU5539596A (en) 1995-04-06 1996-10-23 Amylin Pharmaceuticals, Inc. Anti-obesity agents
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
AU5893796A (en) 1995-06-07 1996-12-30 Novo Nordisk A/S Modification of polypeptides
WO1997000317A1 (en) 1995-06-07 1997-01-03 Osteosa Inc. Osteoclast growth regulatory factor
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
AU695934B2 (en) 1995-06-30 1998-08-27 Eli Lilly And Company Methods for treating diabetes
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
EP0857210B1 (en) 1995-10-23 2003-09-03 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US5854205A (en) 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
AU1407997A (en) 1995-12-01 1997-06-19 Beth Israel Hospital Il-12 p40 subunit fusion polypeptides and uses thereof
IL124831A0 (en) 1995-12-27 1999-01-26 Genentech Inc Ob protein derivatives having prolonged half-life
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US7063958B1 (en) 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
WO1997030089A1 (en) 1996-02-13 1997-08-21 Regents Of The University Of California Novel antibody-cytokine fusion protein, and methods of making and using the same
US5756541A (en) 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
AU2527397A (en) 1996-03-13 1997-10-01 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
CA2205757C (en) 1996-05-30 2006-01-24 F. Hoffmann-La Roche Ag Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
US5922685A (en) 1996-06-05 1999-07-13 Powderject Vaccines, Inc. IL-12 gene therapy of tumors
WO1998000127A1 (en) 1996-07-02 1998-01-08 Bar-Ilan University Retinoyloxy(substituted)alkylene butyrates useful for the treatment of cancer and other proliferative diseases
WO1998006752A1 (en) 1996-08-16 1998-02-19 The Rockefeller University A leptin binding protein and its use in methods for diagnosing and treating abnormalities of the endogenous leptin pathway
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
US5994104A (en) 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
EP1835030A1 (en) 1996-12-20 2007-09-19 Amgen, Inc. OB fusion protein compositions and methods
US6737057B1 (en) 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US6100387A (en) * 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CA2284726A1 (en) 1997-04-11 1998-10-22 G.D. Searle & Co. Antagonistic anti-avb3 integrin antibodies
IL132380A0 (en) 1997-04-17 2001-03-19 Amgen Inc Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
GB9712892D0 (en) 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
WO1999002709A1 (en) 1997-07-10 1999-01-21 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
BR9908226A (pt) * 1998-02-25 2000-10-24 Lexigen Pharm Corp Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
US20030105294A1 (en) 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
CN1318092C (zh) 1998-04-15 2007-05-30 利思进药品公司 含有抗体－细胞因子融合蛋白和血管生成抑制剂的免疫治疗用组合物
HK1038881A1 (zh) 1998-04-17 2002-04-04 利思进药品公司 通过共同给予前列腺素抑制剂增强抗体-细胞因子融合蛋白介导的免疫应答
AU3655899A (en) * 1998-04-20 1999-11-08 Regents Of The University Of California, The Modified immunoglobulin molecules and methods for use thereof
WO1999058662A1 (fr) 1998-05-14 1999-11-18 Merck Patent Gmbh Proteine fusionnee
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
CA2331370A1 (en) 1998-06-03 1999-12-09 The Children's Medical Center Corporation Protein oligomer compositions comprising endostatin protein and methods of using the same
DK1088084T3 (da) 1998-06-15 2007-01-29 Gtc Biotherapeutics Inc Erythropoietin analog-humant serumalbumin fusionsprotein
GB9814383D0 (en) 1998-07-02 1998-09-02 Cambridge Antibody Tech Improvements relating to antibodies
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
JP2002523036A (ja) 1998-08-25 2002-07-30 レキシジェン ファーマシューティカルズ コーポレイション イムノフュージンとしての新脈管形成インヒビターの発現および輸送
US6646113B1 (en) * 1998-09-17 2003-11-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
US6335176B1 (en) * 1998-10-16 2002-01-01 Pharmacopeia, Inc. Incorporation of phosphorylation sites
DE69935345T3 (de) 1998-10-23 2018-03-01 Amgen Inc. Methoden und zusammensetzungen zur prävention und behandlung der anämie
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
MXPA01006922A (es) 1999-01-07 2002-04-24 Lexigen Pharm Corp Expresion y exportacion de proteinas de anti-obesidad como proteinas de fusion en fc.
KR100773109B1 (ko) 1999-05-06 2007-11-02 웨이크 포리스트 유니버시티 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
EP1177285A1 (en) 1999-05-07 2002-02-06 Genentech, Inc. Chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same
US6348192B1 (en) 1999-05-11 2002-02-19 Bayer Corporation Interleukin-2 mutein expressed from mammalian cells
KR20020018197A (ko) 1999-05-19 2002-03-07 추후보정 Ｆｃ 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비
WO2000078334A1 (en) 1999-06-17 2000-12-28 University Of Maryland Biotechnology Institute Chimeric chemokine-antigen polypeptides and uses therefor
PE20010288A1 (es) * 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
US20050202538A1 (en) 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
US8623373B2 (en) 2000-02-24 2014-01-07 Philogen S.P.A. Compositions and methods for treatment of angiogenesis in pathological lesions
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
NZ522320A (en) 2000-05-12 2007-03-30 Neose Technologies Inc In vitro modification of glycosylation patterns of recombinant glycopeptides
CZ2003214A3 (cs) 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
WO2002057435A2 (en) 2001-01-18 2002-07-25 Merck Patent Gmbh Bifunctional fusion proteins with glucocerebrosidase activity
PL362324A1 (en) 2001-02-19 2004-10-18 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
BR0209177A (pt) 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
CA2456470A1 (en) 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
CA2479212A1 (en) 2002-03-15 2003-09-25 Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
US20050069521A1 (en) 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
EP1673395A1 (en) * 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
KR101163424B1 (ko) 2003-12-30 2012-07-13 메르크 파텐트 게엠베하 Ｉｌ－７ 융합 단백질
EP1699821B1 (en) 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
CA2553883C (en) 2004-01-22 2013-04-02 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
US20070104689A1 (en) 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
SI1966238T1 (sl) 2005-12-30 2012-08-31 Merck Patent Gmbh Variante interlevkina-12P40 z izboljšano stabilnostjo
CN101346395A (zh) 2005-12-30 2009-01-14 默克专利有限公司 阻止复合有IL-6Rα的IL-6与GP130结合的抗IL-6抗体
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
JP2009542592A (ja) 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法
US7622522B2 (en) 2007-09-27 2009-11-24 Sabic Innovative Plastics Ip B.V. Flame-retardant poly(arylene ether) composition and its use as a covering for coated wire

Similar Documents

Publication Publication Date Title
WO2004014940A3 (en) PEPTIDES AS SOLUBILIZING EXCIPIENTS FOR TRANSFORMING GROWTH FACTOR ß PROTEINS
WO2001005950A3 (en) Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
DE69938435D1 (de) Niedrigallergene Proteinvarianten
ATE204300T1 (de) Zielzellen-bindende chimäre peptide
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
WO2002002627A3 (en) Interferon-like protein zcyto21
EE05539B1 (et) Hbriidvalk, selle kasutamine, seda sisaldav antikeha v?i selle fragment ja selle kasutamine
ATE401390T1 (de) Zytokin (zcytor17-ligand)
ATE223229T1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
WO2001094413A3 (en) B7-related nucleic acids and polypeptides and their uses for immunomodulation
DE69838143D1 (de) Antimikrobielle peptide
JP2002206000A5 (enExample)
MXPA04000597A (es) Peptidos novedosos de la proteina g del virus sincicial respiratorio (rsv), y su uso en una vacuna.
NZ612319A (en) Single-chain multivalent binding proteins with effector function
ATE280827T1 (de) Penaeidine: antimikrobielle peptide aus krebstieren
WO2001027136A3 (fr) Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
CY1111763T1 (el) ΑΝΤΙΣΩΜΑΤΑ ΕΝΑΝΤΙΟΝ ΤΗΣ ΠΡΩΤΕΪΝΗΣ p51
ATE294816T1 (de) Neue, physiologisch aktive peptide und ihre verwendung.
DE60326581D1 (de) Markierte peptide mit einer affinität für ein phospholipid und deren verwendungen
ATE309351T1 (de) Einkettigen polypeptiden enthalten troponin i und troponin c
HUP9800782A2 (hu) Új antitest, az azt tartalmazó renin-aktív anyag és a prorenin vizsgálatára szolgáló reagens
WO2002030975A3 (en) Antifungal peptides
AU2676399A (en) Novel cystine knot protein and materials and methods for making it
WO2002095076A3 (en) Modified polypeptides having protease-resistance and/or protease-sensitivity
JP2007117090A5 (enExample)